Medicare GLP-1 Bridge Cuts Weight-Loss Drug Costs to $50 a Month for Eligible Seniors

The federal government launched a pilot program on July 1 capping out-of-pocket costs for select GLP-1 weight-loss drugs at $50 a month for qualifying Medicare and Medicare Advantage beneficiaries — a shift that could reshape access for roughly 10 million overweight or obese seniors currently enrolled in the program. The Medicare GLP-1 Bridge covers Eli Lilly's Foundayo tablets and Zepbound KwikPens along with Novo Nordisk's Wegovy injections and tablets, marking the first time GLP-1 medications will be covered by insurance solely for weight loss. The temporary program runs through the end of 2027.

From $1,600 to $50: The Cost Cliff Drops

Before the Bridge program, seniors paid between $1,350 and $1,650 per month for Novo Nordisk's Wegovy (semaglutide) and roughly $1,086 monthly for Eli Lilly's Zepbound (tirzepatide), though both manufacturers offered some cash-pay arrangements that reduced costs for eligible patients. The new $50 monthly cap collapses that barrier in a single policy move.

Jamey Millar, Novo Nordisk's executive vice president of U.S. operations, described the program as "a new, affordable path to an FDA-approved treatment that was previously not covered" for older Americans living with obesity.

Who Qualifies — and Who Is Excluded

Eligibility parameters are narrow. Enrollees must have had a body mass index of 35 or higher when starting GLP-1 therapy, or a BMI of 27 or higher alongside a qualifying condition such as a prior heart attack, stroke, or prediabetes. Those who already carry insurance coverage for conditions like diabetes or sleep apnea are explicitly excluded.

Juliette Cubanski, vice president and director of the program on Medicare policy at the healthcare research nonprofit KFF, put the eligible population in context: more than 70 million Americans are enrolled in Medicare, approximately 10 million of whom are overweight or obese.

CMS Frames Bridge as a Data Exercise, Not a Permanent Fix

Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, positioned the program as both immediate relief and a controlled experiment. CMS plans to carefully track participation and outcomes to determine whether an extension of the Bridge program or a different mechanism is warranted. Oz said ongoing talks with drug companies to lower costs are underway and characterized permanent federal legislation enabling broader GLP-1 coverage as a question "for Congress to debate amongst themselves."

Older Patients Face Distinct Clinical Risks

The access expansion carries a medical caveat specific to this demographic. Dr. Micah Eimer, a clinical assistant professor of cardiology at Northwestern University Feinberg School of Medicine, noted that older patients generally face higher rates of adverse effects from medication. His research found that older patients on blood pressure medications were more likely to experience hypotensive side effects — including fainting and dizziness — after beginning a GLP-1 regimen. That safety signal will almost certainly factor into the outcome data CMS collects before any long-term coverage decision is made.